Navigation Links
Kosan Announces Third Quarter 2007 Financial Results
Date:11/8/2007

President and Chief Executive Officer. "We believe that the growing body of positive clinical data that we have generated in our clinical trials to date, combined with development and regulatory strategies that are being successfully implemented in all of our clinical programs and the commercial potential of our Hsp90 and epothilone programs, position Kosan as an attractive investment opportunity."

Third Quarter 2007 Highlights

-- Kosan reached a binding agreement with the U.S. Food and Drug

Administration (FDA) on the design of Kosan's TIME-1 clinical trial, a

pivotal Phase 3 trial of Kosan's Hsp90 inhibitor tanespimycin as a

treatment for patients with multiple myeloma, through a Special

Protocol Assessment (SPA) process with the FDA. Kosan also completed

the "Scientific Advice" process with the centralized European Medicines

Agency (EMEA) for TIME-1.

-- At the 2007 Breast Cancer Symposium of the American Society of Clinical

Oncology (ASCO), Kosan presented updated data from a Phase 1 clinical

trial showing that Kosan's Hsp90 inhibitor alvespimycin demonstrated

antitumor activity and tolerability in combination with trastuzumab

(Herceptin(R)), with clinical benefit observed in 42% of evaluable

patients (8 of 19 evaluable) with HER2-positive metastatic breast

cancer.

-- Pfizer Inc. initiated a Phase 1 clinical trial designed to test the

safety, tolerability and pharmacokinetics of motilin receptor agonist

KOS-2187, a selective and potent motilin receptor agonist being

developed for the treatment of gastroesophageal reflux disease (GERD)

and potentially other gastrointestinal disorders.

-- Kosan completed preparations and is planning to initiate later this

quarter a Phase 2 clinical trial of alvespimycin in patients with

newly-diagnosed HER2-positive metastatic breast cance
'/>"/>

SOURCE Kosan Biosciences Incorporated
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. Kosan Biosciences to Present at the Bear Stearns 20th Annual Healthcare Conference
2. Kosan Biosciences to Present at the 2007 UBS Global Life Sciences Conference
3. Kosan Biosciences to Present at the Biotechnology Industry Organization Investor Forum
4. Kosan Biosciences to Host Research & Development Day on October 31, 2007
5. Kosan to Reacquire Epothilone Program From Roche
6. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
7. YM BIOSCIENCES ANNOUNCES COMPLIANCE WITH AIM RULE 26
8. Emisphere Technologies, Inc. Announces Pricing of Registered Direct Offering
9. BioLife Solutions Announces Exclusive CryoStor(TM) Supply Agreement With the New England Cryogenic Center, Inc.
10. Carrington Announces Nasdaq Communication; Prepares for Shares to Be Quoted on the OTC Bulletin Board and Pink Sheets
11. China Kangtai Cactus Biotech Files 2nd Quarter 2007 10QSB and Announces Unaudited Quarterly Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2014)... The first product launch from start-up ... to robotics. What sets Droidles completely apart from other ... allows them to communicate, share code with each other ... , “The invention is the system,” said Hurley Research ... life of their own, both physically and on the ...
(Date:7/29/2014)... (PRWEB) July 29, 2014 The prestigious ... of Congress was recently awarded to Juliana Hillis and ... MA, for their project, “From an Egg, Everything: America’s ... 3,000 final entries for the National History Day program ... 300 historians and educators in Washington, D.C. , The ...
(Date:7/29/2014)... July 29, 2014 White papers ... and cloud based eClinical technologies, have been published by ... These follow a long line of white papers by ... including Life Science Leader, Pharmaceutical Online, and OpenHealthNews. , ... a paper by CTO Marc Desgrousilliers, 'The Five ...
(Date:7/29/2014)... July 29, 2014 ... (LBS) zur Erfassung biologischer Daten in Verbindung ... und patentiert. Das LBS nimmt gleichzeitig mehrere ... des Patienten und sucht erhöhte biologische Aktivitäten ... Potenzial, die Entdeckung und Entwicklung neuer Medikamente ...
Breaking Biology Technology:Droidles, the Social Network of Robots and Open Source Platform for the Internet of Things, Launches for Crowd Funding on IndieGoGo.com 2In Vitro Fertilization (IVF) was the Subject of This Year’s Winning Entry for the Prestigious Library of Congress “Discovery or Exploration in History Award” 2In Vitro Fertilization (IVF) was the Subject of This Year’s Winning Entry for the Prestigious Library of Congress “Discovery or Exploration in History Award” 3Clinovo White Papers Published in Summer 2014 Editions of Leading Medical Device & Pharmaceutical Publications 2Clinovo White Papers Published in Summer 2014 Editions of Leading Medical Device & Pharmaceutical Publications 3PlaqueTec sichert sich CE-Kennzeichnung für Liquid Biopsy System - bahnbrechende Innovation zur Erfassung neuer biologischer Informationen aus erkranktem Herzkranzgefäß 2PlaqueTec sichert sich CE-Kennzeichnung für Liquid Biopsy System - bahnbrechende Innovation zur Erfassung neuer biologischer Informationen aus erkranktem Herzkranzgefäß 3PlaqueTec sichert sich CE-Kennzeichnung für Liquid Biopsy System - bahnbrechende Innovation zur Erfassung neuer biologischer Informationen aus erkranktem Herzkranzgefäß 4
... only Web-based solution for managing compliance and regulated content throughout ... , SAN DIEGO, June 22 Drug ... Virtify, Inc. , the market leader in enterprise ... upcoming release of its Virtx integrated software suite, an end-to-end, ...
... alternative to Singulair and Zicam - The ALCAT Test , ... FDA knocked the wind out of asthmatics by requesting the ... drug, to upgrade their warning against psychotic side effects. Further ... also last week announced warnings that the drug may cause ...
... , , SINGAPORE, June 22 Globally, the largest ... achieve a reduction in CO2 emissions by 8.0 percent between 2008 ... 5.75 percent bio-fuels of all transportation fuel by December 2010 and ... market, it is witnessing rapid growth in terms of both new ...
Cached Biology Technology:Virtify, Inc. Delivers Industry's First Enterprise Content Compliance Software Suite for Life Sciences Companies 2Virtify, Inc. Delivers Industry's First Enterprise Content Compliance Software Suite for Life Sciences Companies 3Virtify, Inc. Delivers Industry's First Enterprise Content Compliance Software Suite for Life Sciences Companies 4Virtify, Inc. Delivers Industry's First Enterprise Content Compliance Software Suite for Life Sciences Companies 5Knocking the Wind Out of Asthmatics: Help from Hippocrates 2Government Mandates Create Guaranteed Market for Bio-Fuel, Says Frost & Sullivan 2Government Mandates Create Guaranteed Market for Bio-Fuel, Says Frost & Sullivan 3Government Mandates Create Guaranteed Market for Bio-Fuel, Says Frost & Sullivan 4
(Date:7/28/2014)... of Medicine have pinpointed a mechanism in part of the ... blood, linking it to both type 1 and type 2 ... of Proceedings of the National Academies of Sciences . ... located in a part of the hypothalamus known as the ... that control glucose levels in the blood," said lead author ...
(Date:7/28/2014)... the top 10 U.S. cities that have seen an ... as frequent road closures, overwhelmed storm drains and compromised ... NOAA technical report. , This nuisance flooding, caused by ... coasts, between 300 and 925 percent since the 1960s. ... Frequency Changes around the United States, also finds Annapolis ...
(Date:7/28/2014)... has identified areas of the Earth that are high ... , Europe is particularly vulnerable, as it has the ... cent, of any continent in ,refugia, areas of ... conditions remain relatively constant during times of great environmental ... mostly in Scandinavia and Scotland. , The biggest ...
Breaking Biology News(10 mins):Glucose 'control switch' in the brain key to both types of diabetes 2NOAA: 'Nuisance flooding' an increasing problem as coastal sea levels rise 2NOAA: 'Nuisance flooding' an increasing problem as coastal sea levels rise 3Study finds Europe's habitat and wildlife is vulnerable to climate change 2
... TORONTO, ON A team of University of Toronto chemists ... quantum biology, observing quantum mechanics at work in photosynthesis in ... speculation that nature may be using quantum mechanical practices," says ... published this week in Nature . "Our latest ...
... that glaciers in the Himalayan mountains are thinning is ... examine and quantify the causes. Lawrence Berkeley National Laboratory ... of the most commonly blamed culpritgreenhouse gases, such as ... be causing the melting. Menon and her collaborators found ...
... For Immediate Release A team of scientists at ... on novel binding sites for an enzyme used by the ... discovery lays the foundation for the development of a new ... strains of the disease, and slow the evolution of drug ...
Cached Biology News:Scientists find quantum mechanics at work in photosynthesis 2Black carbon a significant factor in melting of Himalayan glaciers 2Black carbon a significant factor in melting of Himalayan glaciers 3Scripps Research scientists find two compounds that lay the foundation for a new class of AIDS drug 2Scripps Research scientists find two compounds that lay the foundation for a new class of AIDS drug 3Scripps Research scientists find two compounds that lay the foundation for a new class of AIDS drug 4Scripps Research scientists find two compounds that lay the foundation for a new class of AIDS drug 5
Sheep polyclonal to Streptomycin ( Abpromise for all tested applications). Antigen: Chemical / Small Molecule: Streptomycin conjugated to BSA....
Rabbit polyclonal to MAL ( Abpromise for all tested applications). entrezGeneID: 4118 SwissProtID: P21145...
Glutamate Receptor 5/1a...
Mouse monoclonal [3G8] to MDMA ( Abpromise for all tested applications)....
Biology Products: